Company Encyclopedia
View More
name
Endra Life Sciences
NDRA.US
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. ENDRA Life Sciences Inc.
1.391 T
NDRA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ENDRA Life Sciences Reports TAEUS Device Matches MRI Accuracy in Liver Disease Study

    ENDRA Life Sciences Inc. announced that its TAEUS® Liver device closely matches MRI accuracy in detecting liver fat fraction, crucial for clinical decisions. The study showed 100% PPV and 95% accuracy at 12-17% LFF, and 90% PPV and 94% accuracy at 20-22% LFF. A second study is underway, with FDA engagement planned for 2026.

    Reuters·
    US
    NDRA
    +1.98%
    US
    29273B500
    0.00%
    Reuters·
    US
    NDRA
    +1.98%
    US
    29273B500
    0.00%

    ENDRA Life Sciences Announces Management Changes

    On November 28, 2025, ENDRA Life Sciences Inc. announced the resignation of Michael Thornton as Chief Technology Officer. Mr. Thornton will continue to provide services under a new consulting agreement.IndividualMichael ThorntonRoleChief Technology OfficerType of ChangeResignedEffective DateNovember 28, 2025ReasonEntered into a Consulting AgreementReplacement InfoNot disclosedBackground DetailsN/ABoard/Committee Role ChangesNot disclosedOriginal SEC Filing: ENDRA Life Sciences Inc. [ NDRA ] - 8-K - Nov. 28, 2025DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

    TradingView·
    US
    29273B500
    0.00%
    US
    NDRA
    +1.98%
    TradingView·
    US
    29273B500
    0.00%
    US
    NDRA
    +1.98%

    U.S. Stock Market Midday Update: ENDRA Life Sciences up 13.72%, trading volume increased, volatility significantly attracts attention

    ENDRA Life Sciences rose 13.72%; Stryker fell 0.70%, with a transaction volume of USD 291 million; Intuitive Surgical fell 0.46%, with a transaction volume of USD 254 million; Abbott rose 0.65%, with a transaction volume of USD 235 million; Boston Scientific rose 0.27%, with a market capitalization of USD 150.7 billion

    Tracking Unusual Activity·
    US
    NDRA
    +1.98%
    Tracking Unusual Activity·
    US
    NDRA
    +1.98%

    ENDRA Life Sciences Reports Positive Feasibility Study Results for TAEUS Liver Fat Quantification Device

    ENDRA Life Sciences announced positive preliminary results from a feasibility study of its TAEUS Liver device for quantifying liver fat, showing strong agreement with MRI-PDFF. The results will inform a pivotal study design with the FDA. A second study is underway in Canada, with results to be published and discussed with the FDA.

    Reuters·
    US
    29273B500
    0.00%
    US
    NDRA
    +1.98%
    Reuters·
    US
    29273B500
    0.00%
    US
    NDRA
    +1.98%

    ENDRA Life Sciences reports third quarter cash burn down 30% to $1.2 million

    ENDRA Life Sciences reported a 30% reduction in cash burn for Q3 2025, totaling $1.2 million, down from $1.7 million in Q3 2024. Operating expenses decreased to $1.4 million. The company had $0.8 million in cash as of September 30, 2025, and raised $4.9 million through a private placement, regaining Nasdaq compliance. ENDRA completed a clinical study of its TAEUS Liver device and launched a strategic initiative to enhance balance sheet flexibility.

    Reuters·
    US
    29273B500
    0.00%
    US
    NDRA
    +1.98%
    Reuters·
    US
    29273B500
    0.00%
    US
    NDRA
    +1.98%
    © 2025 Longbridge｜Disclaimer